Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Immunotherapy Adjuvant Trial in Patients with Stage I-III Merkel Cell Carcinoma
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 120
- Registration Number
- NCT04291885
- Locations
- π¦πΊ
Cancer Care Wollongong, Wollongong, New South Wales, Australia
π¦πΊTasman Health Care, Southport, Queensland, Australia
π¦πΊPort Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04266912
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 38
- Registration Number
- NCT04261855
- Locations
- π¦πΊ
Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
π¦πΊRoyal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
π¦πΊRoyal North Shore Hospital, Sydney, New South Wales, Australia
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04242238
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 48
- Registration Number
- NCT04215146
- Locations
- πΊπΈ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈThomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 42
- Registration Number
- NCT04188119
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 47
- Registration Number
- NCT04173507
- Locations
- πΊπΈ
Parkview Regional Medical Center, Fort Wayne, Indiana, United States
πΊπΈPalo Alto Medical Foundation-Camino Division, Mountain View, California, United States
πΊπΈSanford Bismarck Medical Center, Bismarck, North Dakota, United States
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04068831
- Locations
- πΊπΈ
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
πΊπΈMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT04071236
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUSC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 101
- Registration Number
- NCT04068194
- Locations
- πΊπΈ
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
πΊπΈUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
πΊπΈUniversity of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.